BIIB Biogen Inc.

247.13USD-1.70%Mkt Cap: 36.53B USDP/E: 106.98

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…

Institutional holders20 on file

Key Statistics

Company
Market Cap36.53B USD
Enterprise Value43.66B USD
Revenue (TTM)10.30B USD
Gross Profit7.49B USD
Net Income (TTM)1.29B USD
Revenue/Share69.89 USD
Last Price247.13 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees7.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISIN—
Valuation
P/E (Trailing)106.98
P/E (Forward)15.22
PEG3.42
EV/EBITDA13.22
EV/Revenue4.24
P/S3.55
P/B1.93
EPS (TTM)2.34 USD
EPS (Forward)16.26 USD
52W Range
151.8387% of range261.00
52W High261.00 USD
52W Low151.83 USD
Profitability
Gross Margin75.69%
Oper. Margin23.50%
EBITDA Margin32.07%
Profit Margin13.07%
ROE7.08%
ROA4.39%
ROIC9.76%
ROCE9.46%
Growth
Revenue Growth10.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF2.20B USD
CapEx (TTM)235.40M USD
FCF Margin7.85%
FCF Yield2.21%
Net Debt6.50B USD
Net Debt/EBITDA1.97
Net Debt/FCF8.04
Balance Sheet
Debt/Equity0.36
Current Ratio1.95
Quick Ratio0.95
Book Value/Sh128.03 USD
Cash/Share8.82 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split3:1
Split DateJan 18, 2001
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)268.26 USD
Upside (mean)+8.6%
Target Range175.00 USD – 350.00 USD
175.00+8.6% to mean350.00
# Analysts32
Ownership
Shares Out.147.82M
Float147.29M
Insiders0.21%
Institutions100.37%
Short Interest
Short Ratio4.0d
Short % Float4.11%
Short % Out.3.69%
Shares Short5.45M
Short (prev mo.)5.97M
Technical
SMA 50233.96 (+5.6%)
SMA 200205.51 (+20.3%)
Beta0.09
S&P 52W Chg12.08%
Avg Vol (30d)1.22M
Avg Vol (10d)1.03M
Technical Indicators
RSI (14)51.5
MACD4.0128
MACD Signal5.3064
MACD Hist.-1.2936
BB Upper256.94 USD
BB Middle250.70 USD
BB Lower244.47 USD
BB Width4.97%
ATR (14)7.304 USD
Vol Ratio (20d)1.06x

About Biogen (NASDAQ: BIIB)

›

Biogen (NASDAQ: BIIB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 7,500 employees.

The shares were at 247.13 USD on 19 November 2026, up 57.7% over 52 weeks. Its 52-week range is 151.83 USD to 261.00 USD: the price is 5.3% below the high and 62.8% above the low.

At a market capitalisation of 36.53B USD, it trades at 107.0 times trailing earnings and 15.2 times forward earnings. The median trailing P/E of its 19 largest Drug Manufacturers - General peers is 26.0, a premium of 311% for BIIB.

Biogen reports return on equity of 7.1%, an operating margin of 23.5% and revenue up 10.6% year over year.

Its debt exceeds its cash by 6.50B USD, a debt-to-equity ratio of 0.36. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 32 analysts cover the stock, with an average rating of Buy; their mean price target of 268.26 USD is 8.6% above the current price. The next earnings report is expected on 5 February 2027.